Silatecan

DB12384InvestigationalSmall molecule

Silatecan has been used in trials studying the treatment of GBM, Tumors, Gliosarcoma, Solid Malignancies, and Glioblastoma Multiforme, among others.

Chemical structure of Silatecan
Mechanism
Curator reviewed
Formula / weight
C26H30N2O5Si · 478.62 g/mol (avg)
Code names
AR-67 · DB-67

Resolves to

Compound
UNII3YEA04NV6HCAS220913-32-6ChEMBLCHEMBL412309PubChem6712744
Structure
InChIKeyXUSKJHCMMWAAHV-SANMLTNESA-NSMILESCC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=CC1=C3[Si](C)(C)C(C)(C)C)C2=O
Targets
P11387TOP1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Silatecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In